Role of telitacicept in the treatment of IgA nephropathy

• Published in: European journal of medical research Vol. 28; no. 1; pp. 1 - 369
• Main Authors: Wu, Lijun, Du, Xinru, Lu, Xuehong
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 22.09.2023; BioMed Central; BMC
• Subjects: APRIL; Autoimmunity; B cells; BAFF; Belimumab; Blood pressure; BLyS; Chinese medicine; Chronic kidney failure; Clinical trials; Cytokines; IgA; Immunoglobulin A; Immunosuppressive agents; Lymphocytes; Monoclonal antibodies; Nephropathy; Pathophysiology; Patients; Plasma; Proteins; Review; Telitacicept; Tumor necrosis factor-TNF; Urine; China
• ISSN: 2047-783X; 0949-2321; 2047-783X
• DOI: 10.1186/s40001-023-01320-2

IgA nephropathy (IgAN) is the most common primary glomerular disease in the world, and up to 40% of patients with IgAN develop end-stage renal disease (ESRD). At present, an increasing amount of evidence indicates that the pathogenesis of IgAN is related to autoimmunity. In recent years, several studies have shown that B cell activating factors (BAFF), also known as B lymphocyte stimulators (BLyS), and proliferation-inducing ligand APRIL are extremely important for the activation of autoimmune signalling pathways, which have become key targets for the treatment of IgAN. As a dual-target biological agent, telitacicept can inhibit both BLyS and APRIL cytokines, improve the function of renal immune complexes, and reduce haematuria and proteinuria, which play important roles in IgAN pathogenesis and long-term prognosis. This article reviews the role of telitacicept in IgA nephropathy and discusses its potential for use in the treatment of IgAN and other autoimmune diseases where pathogenesis is driven by B cells.